Oncology
Latest news
915 articles · 20 / page
Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection
A multicenter study demonstrates that prioritizing endoscopic submucosal dissection (ESD) for Barrett’s cancers >15mm significantly improves R0 resection rates and survival, particularly in T1b disease, compared to traditional endoscopic mu
GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients
A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for d
Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks
An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of g
New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis
A landmark study in Gastroenterology reveals that APC mosaicism accounts for nearly 10% of unexplained colorectal polyposis. New guidelines recommend specific testing thresholds and surveillance strategies to prevent colorectal cancer in th
Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma
The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat
Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling
Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vuln
The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer
A comprehensive multi-omics study reveals that Faecalibacterium prausnitzii metabolizes tryptophan into picolinic acid, which antagonizes the pro-tumorigenic effects of enterotoxigenic Bacteroides fragilis by down-regulating TCERG1 and CKAP
Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort
This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for
Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling
This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT
Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules
A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for approp
Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program
This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial
Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial
A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survi
Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy
A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standa
Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?
The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and
SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease
The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for pati
Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers
A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer p
The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension
Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hi
Surgical Management of Sporadic Medullary Thyroid Cancer: Evidence-Based Comparison of Total Thyroidectomy vs Lobectomy
This systematic review and meta-analysis suggests that thyroid lobectomy may offer comparable oncologic outcomes to total thyroidectomy for selected patients with sporadic medullary thyroid cancer, while significantly reducing postoperative
Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of di
Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma
Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signa
Browse by specialty
Open language-specific specialty feeds and department pages.